Close Menu

Agilent

For the three months ended April 30, the firm's revenues were $1.24 billion, flat with $1.24 billion in Q2 2019 but beating Wall Street analysts' average estimate of $1.21 billion.

Agilent, which co-led Mission Bio's 2018 $30 million Series B financing round, will comarket the Tapestri platform to cancer researchers in North America.

The firm noted a disruption in global business in late March, as customers closed or restricted access to their facilities in an attempt to slow the spread of the coronavirus.

The Stanford University spinout claims it can get three times the nucleic acid yield as column- or magnetic bead-based methods, with less damage to the molecules.

For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.

On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.

The company booked a net loss of $55.6 million, or $1.69 per share, for the quarter which included litigation settlement expenses of $22.5 million.

A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.

Pages

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.